- Home
- ANAB vs SBSI Comparison
ANAB vs SBSI Comparison
Compare ANAB & SBSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SBSI
- Stock Information
- Founded
- ANAB 2005
- SBSI 1960
- Country
- ANAB United States
- SBSI United States
- Employees
- ANAB N/A
- SBSI 778
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SBSI Major Banks
- Sector
- ANAB Health Care
- SBSI Finance
- Exchange
- ANAB Nasdaq
- SBSI Nasdaq
- Market Cap
- ANAB 759.5M
- SBSI 866.8M
- IPO Year
- ANAB 2017
- SBSI N/A
- Fundamental
- Price
- ANAB $22.23
- SBSI $28.18
- Analyst Decision
- ANAB Buy
- SBSI Hold
- Analyst Count
- ANAB 10
- SBSI 2
- Target Price
- ANAB $42.25
- SBSI $37.00
- AVG Volume (30 Days)
- ANAB 559.5K
- SBSI 99.1K
- Earning Date
- ANAB 05-05-2025
- SBSI 07-24-2025
- Dividend Yield
- ANAB N/A
- SBSI 5.11%
- EPS Growth
- ANAB N/A
- SBSI 7.94
- EPS
- ANAB N/A
- SBSI 2.91
- Revenue
- ANAB $111,872,000.00
- SBSI $254,817,000.00
- Revenue This Year
- ANAB N/A
- SBSI $10.28
- Revenue Next Year
- ANAB $9.72
- SBSI $5.20
- P/E Ratio
- ANAB N/A
- SBSI $9.69
- Revenue Growth
- ANAB 387.20
- SBSI 6.49
- 52 Week Low
- ANAB $12.21
- SBSI $25.30
- 52 Week High
- ANAB $41.31
- SBSI $38.00
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- SBSI 44.52
- Support Level
- ANAB $20.50
- SBSI $27.92
- Resistance Level
- ANAB $22.84
- SBSI $28.72
- Average True Range (ATR)
- ANAB 1.28
- SBSI 0.48
- MACD
- ANAB 0.12
- SBSI -0.13
- Stochastic Oscillator
- ANAB 83.24
- SBSI 22.79
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SBSI Southside Bancshares Inc.
Southside Bancshares Inc is a bank holding company. Through its subsidiary, the Southside Bank, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.